NewsEvents

Your Yourlocation: Home > Clinical analysis of tiotropium bromide(136310-93-5) in the treatment of moderate to severe chronic obstructive pulmonary disease

To investigate the effect of tiotropium bromide(136310-93-5) in the treatment of stable stage Ⅲ ~ Ⅳ chronic obstructive pulmonary disease(COPD).

Methods: 34 patients with stable grade Ⅲ ~ Ⅳ COPD were randomly divided into two groups. The control group (18 g /s) was in the control group (18 g /s), the control group (inhaled ipratropium bromide 40 g, 4 times /d) in 16 cases. The lung function was measured before and 2 weeks after treatment.

Results: After treatment, the percentage of FEV1, FEV1 / FVC, FEV1 in the test group was higher than that before treatment (0.01). The percentage of FEV1 /FVC and FEV1 in the control group was higher than that before treatment (0.01) (P <0.05). There was no significant difference between FEV1, FEV1 /FVC and FEV1 in the two groups (P> 0.05).

Conclusion: Tiotropium bromide(136310-93-5) can significantly improve lung function in COPD patients with ipratropium bromide.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved